ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated at Jefferies Financial Group

Analysts at Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report released on Friday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $80.00 price target on the specialty pharmaceutical company’s stock. Jefferies Financial Group’s price target indicates a potential upside of 28.02% from the company’s previous close.

ANIP has been the subject of several other research reports. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a research note on Wednesday. They set an “overweight” rating and a $85.00 price target on the stock. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Finally, Guggenheim upped their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $79.75.

ANI Pharmaceuticals Trading Up 1.7 %

NASDAQ:ANIP opened at $62.49 on Friday. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock has a fifty day moving average price of $58.40 and a two-hundred day moving average price of $58.09. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of 0.62.

Insider Transactions at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,700 shares of company stock valued at $610,201 over the last three months. 12.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ANIP. Principal Financial Group Inc. boosted its stake in ANI Pharmaceuticals by 6.9% in the 3rd quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock worth $5,367,000 after buying an additional 5,829 shares during the last quarter. Victory Capital Management Inc. grew its holdings in ANI Pharmaceuticals by 153.6% in the third quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock valued at $771,000 after purchasing an additional 7,825 shares during the period. Mizuho Markets Americas LLC purchased a new position in ANI Pharmaceuticals during the third quarter worth approximately $11,670,000. Natixis Advisors LLC boosted its holdings in shares of ANI Pharmaceuticals by 56.2% in the 3rd quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock valued at $1,085,000 after purchasing an additional 6,545 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its holdings in shares of ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after purchasing an additional 299 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.